Refine
Has Fulltext
- yes (19) (remove)
Is part of the Bibliography
- yes (19)
Year of publication
Document Type
- Doctoral Thesis (19)
Keywords
- Dendritische Zelle (19) (remove)
Institute
- Graduate School of Life Sciences (19) (remove)
The human pathogen Aspergillus (A.) fumigatus is a fungal mold that can cause severe infections in immunocompromised hosts. Pathogen recognition and immune cell cross-talk are essential for clearing fungal infections efficiently. Immune cell interactions in particular may enhance individual cell activation and cytotoxicity towards invading pathogens.
This study analyzed the reciprocal cell activation of natural killer (NK) cells and monocyte-derived dendritic cells (moDCs) after stimulation with A. fumigatus cell wall fractions and whole-cell lysates. Furthermore, the impact of the on moDCs expressed fungal receptors Dectin-1 and TLR-2 on NK cell activation was analyzed. Stimulation of moDCs with ligands for Dectin-1 and TLR-2 and transfer of soluble factors on autologous NK cells showed that moDCs could induce NK cell activation solely by secreting factors. In summary, both cell types could induce reciprocal cell activation if the stimulated cell type recognized fungal morphologies and ligands. However, moDCs displayed a broader set of A. fumigatus receptors and, therefore, could induce NK cell activation when those were not activated by the stimulus directly.
Consequently, new fungal receptors should be identified on NK cells. The NK cell characterization marker CD56 was reduced detected in flow cytometry after fungal co-culture. Notably, this decreased detection was not associated with NK cell apoptosis, protein degradation, internalization, or secretion of CD56 molecules. CD56 was shown to tightly attach to hyphal structures, followed by its concentration at the NK-A. fumigatus interaction site. Actin polymerization was necessary for CD56 relocalization, as pre-treatment of NK cells with actin-inhibitory reagents abolished CD56 binding to the fungus. Blocking of CD56 suppressed fungal mediated NK cell activation and secretion of the immune-recruiting chemokines MIP-1α, MIP-1β, and RANTES, concluding that CD56 is functionally involved in fungal recognition by NK cells.
CD56 binding to fungal hyphae was inhibited in NK cells obtained from patients during immune-suppressing therapy after allogeneic stem cell transplantation (alloSCT). Additionally, reduced binding of CD56 correlated with decreased actin polymerization of reconstituting NK cells challenged with the fungus. The immune-suppressing therapy with corticosteroids negatively influenced the secretion of MIP-1α, MIP-1β, and RANTES in NK cells after fungal stimulation ex vivo. Similar results were obtained when NK cells from healthy donors were treated with corticosteroids prior to fungal co-culture. Thus, corticosteroids were identified to have detrimental effects on NK cell function during infection with A. fumigatus.
Die Unterscheidung zwischen körpereigenen und körperfremden Strukturen ist eine grundlegende Herausforderung der spezifischen Immunantwort. Pathologische Veränderungen dieser Abgrenzung können zu schwerwiegenden Autoimmunerkrankungen wie beispielsweise Diabetes Mellitus, Rheumatischer Arthritis oder Multipler Sklerose führen. Um unerwünschte (Auto-) Immunreaktionen zu verhindern, existieren verschiedene Formen von peripheren Toleranzmechanismen, die durch viele Transkriptionsfaktoren wie z. B. ICER (inducible cAMP early repressor), NFAT (nuclear factor of activated T cells) und Foxp3 (forkhead box protein p3) kontrolliert werden. Foxp3+ regulatorische T-Zellen (Tregs) sind spezialisierte immun-suppressive Lymphozyten, welche die Aktivierung anderer Immunzellen unterdrücken können. Einer der möglichen Mechanismen ist der Transfer zyklischen Adenosin-Monophosphats (cAMP) von Tregs in konventionelle T- und B-Lymphozyten. Die erhöhte intrazelluläre Konzentration an cAMP führt in Effektorzellen zur Induktion und Kerntranslokation von ICER. Der transkriptionelle Repressor ICER supprimiert die Expression vieler NFAT-regulierter Gene und hemmt darüber hinaus die Induktion der NFATc1/αA-Isoform selbst. Diese Isoform wird speziell in pro-inflammatorischen Effektorzellen hochreguliert und ist maßgeblich an deren spezifischem transkriptionellen Programm beteiligt. Foxp3 ist ein zentraler Faktor für die Bildung und Funktion sowohl Thymus-generierter nTregs als auch peripher (TGFβ-) induzierter iTregs. Die Kontrolle des Foxp3-Gens wird in iTregs – überraschenderweise aber nicht in nTregs – durch NFAT-Faktoren reguliert. Allerdings hemmt Foxp3 durch eine negative Rückkopplung wiederum die Induktion und Aktivität von NFATc1/αA. Dies stellt somit ein weiteres Regulativ dar, wobei Foxp3 nicht nur die Plastizität, sondern auch die Funktion von immun-suppressiven T-Zellen steuert. Zusätzlich regulieren die verschiedenen NFAT-Faktoren auch die Antigen präsentierenden dendritischen Zellen (DCs). Während NFATc1 und NFATc2 die Differenzierung und Proliferation von DCs beeinflussen, reguliert NFATc3 deren Zytokinexpression und steuert indirekt auch die nachfolgende T-Zell-Immunantwort. Die Kontrolle der Genregulation in Immunzellen durch die Transkriptionsfaktoren ICER, NFAT und Foxp3 erfüllt somit spezifische Funktionen der Immunität, reguliert aber gleichzeitig wichtige Aspekte der peripheren Toleranz, um schädliche (Auto-) Immunreaktionen zu verhindern.
Semaphorin receptors in the immunological synapse: regulation and measles virus-driven modulation
(2010)
Measles virus (MV) infection causes approximately 164,000 deaths per year worldwide (WHO, 2008). The main cause of death is MV-induced immunosuppression but the underlying mechanisms are not fully understood. It has been suggested that MV renders T cells dysfunctional by disrupting the integrity of actin dynamics while MV infection of dendritic cells results in their inability to sustain T cell activation. During neuronal development, semaphorins (SEMAs), especially SEMA3A, induce a collapse of growing dendrites via the binding to plexin-A1 (plexA1) and its coreceptor neuropilin-1 (NP-1). The collapse results from a disruption of actin dynamics. In this study, the roles of these three molecules were investigated in human immune cells and their possible role in MV induced immunosuppression. The present data have shown that plexA1 is an important component of human immunological synapse (IS). It translocated transiently to the surface of T cells after CD3/28 ligation and accumulated at the stimulatory interface between T cells and DCs (or CD3/28 coated beads). When plexA1 expression was inhibited (RNAi) or its function was disrupted (exogenous blocking or dominant negative expression), T cell expansion was reduced. Upon MV exposure, translocation of plexA1 and NP-1, another important component of IS, towards the stimulatory interface in T cells was abrogated. Moreover, MV infection interfered with plexA1/NP-1 turnover in maturing DCs and promoted early and substantial release of SEMA3A from these cells, particularly in the presence of allogenic T cells. As revealed by scanning electron microscopy, the release of SEMA3A caused a transient loss of actin-based protrusions on T cells. SEMA3A affected chemotactic migration of T cells and DCs, and reduced formation of allogenic DC/T cell conjugates. In conclusion, MV targeted SEMA receptor function both by disrupting their recruitment to the IS and by promoting a premature release of their repulsive ligand, SEMA3A. Both of which could contribute to MV-induced immunosuppression.
Dendritic cell-based vaccination is a well established technique for preventive and therapeutic instruction of the immune system where conservative vaccine formulations fail to cure or prevent diseases, respectively. Efficiency of this technique already was demonstrated in infectious diseases as well as for cancer in animal or human studies. Well controlled manipulation and antigen-loading of immature DC is most beneficial to this technique. But, time-consuming and cost-extensive procedures for preparation of DC precursors, expansion and stimulation of DC and inpatient administration are big disadvantages regarding vaccine development for pandemic infectious diseases that occur mainly in underdeveloped countries. Therefore vaccines are needed that are pathogen-tailored and able to induce equal immune responses as their DC-based vaccine models. For vaccination against Leishmania parasites such a DC-based vaccine is feasible and its efficacy to induce protective Th1-based immune responses was already demonstrated in several animal studies. But, one of our own studies indicated supportive activity of host cells exceeding the allocation of T cells to become activated by transferred DC. IL-12, an important cytokine for the induction of Th1-related immune responses, has to be produced by host cells. Therefore, the aim of this study was to investigate the mechanism of BMDC-based vaccination with regard to simplification of the vaccine formulation. Key questions that have been addressed are: Which cells process the information that is transferred by the injected DC and what are the key components of this information? Further more, it was looked at whether altered vaccine formulations are able to induce protective immunity and whether they share equal molecular mechanisms. The current paradigm of BMDC-based vaccination proposes direct interaction of transferred BMDC with host T cells. These BMDC have to be antigen-loaded for stimulation via antigen-peptide-MHC molecule-complexes and they have to be activated for proper co-stimulation of T cells. Here, this study demonstrates that neither activation for co-stimulation nor direct interaction with adequate MHC molecules is needed for the induction of protective immunity against infection with Leishmania-parasites. Disrupted antigen-loaded BMDC are able to induce protective immunity in BALB/c mice without pre-stimulation via CpG ODN. Beyond, if BMDC were used with a different MHC-background than recipient mice then the vaccine still would be efficient in terms of reduction of footpad swelling and parasite load in draining lymph nodes. Even more, DC-specific features are no key component that leads to protective immunity as vaccination with disrupted antigen-loaded MΦ shows equal properties than before mentioned vaccine formulations. Further more, it was found that host DC play a major role in transforming the incoming signal, received from transferred antigen-loaded DC, into Th1-related stimuli and Leishmania-antigen-specific T cell activation. Suspensions of disrupted antigen-loaded DC resemble a combination of laid off soluble molecules together with exosome-like vesicles that formed after disruption of membranes. Here it was shown that separation of the membranous and soluble fractions and subsequent transfer into BALB/c mice will lead to protection of these mice against infection with L. major promastigotes only if the membranous fraction is used as vaccine. More, this vaccine formulation takes advantage of easy storage at -80°C with no need of fresh production. This clearly demonstrates that the immunity-inducing principle of disrupted DC-based vaccination lies within the membrane enclosed fraction. On a molecular level, disrupted antigen-loaded DC induce Th1-related cytokines during vaccination and as response on pathogen encounter. In vivo assays revealed IL-12 production and antigen-specific T cell proliferation among splenocytes that were stimulated with disrupted antigen-loaded DC. Splenocytes of accordingly vaccinated mice produce tremendous amounts of IFNγ after stimulation with Leishmania parasites. In summary, disrupted antigen-loaded BMDC fulfil all characteristics of DC-based vaccination against Leishmania major. But, while purification of membranes of antigen-loaded DC and subsequent transfer to BALB/c mice leads to control of the disease in the animal model, only slight levels of Th1-related cytokines are seen in the in vivo assays. Whether this points towards a loss of vaccine activity on unseen levels or unknown sites where Th1-related immunity is induced by both, complete solution and purified membranes, still has to be determined.
Effective T cell immunity was believed to occur by mature DC, whereas tolerogenicity was attributed strictly to immature DC phenotypes. However, intermediate DC maturation stages were identified conditioned by inflammatory mediators like TNF. Furthermore, the T cell tolerance mechanisms are dependent on distinct modes and intensities of co-stimulation. Therefore, in this study it was addressed how distinct DC maturation signatures instruct CD4+ T cell tolerance mechanisms. DC acquire antigens from apoptotic cells for self-peptide-MHC presentation and functionally adapt presumed tolerogenic DC phenotypes. Here, immature murine bone-marrow derived DC representing both inflammatory and conventional DC subsets adapted a maturationresistant DC signature upon apoptotic cell recognition but no additional tolerogenic features. Immature DC instruct CD4+ FoxP3+ regulatory T cells in a TGF-β prone micro-environment or generate anergic CD4+ T cells hampered in the TCR-induced proliferation and IL-2 secretion. Secondary stimulation of such anergic CD4+ T cells by immature DC increased primarily IL-10 production and conferred regulatory function. These IL-10+ regulatory T cells expressed high levels of CTLA-4, which is potently induced by immature DC in particular. Data in this work showed that anergic T cells can be re-programmed to become IL-10+ regulatory T cells upon ligation of CTLA-4 and CD28 signalling cascades by B7 costimulatory ligands on immature DC. In contrast, semi-mature DC phenotypes conditioned by the inflammatory mediator TNF prevented autoimmune disorders by induction of IL-10+ Th2 responses as demonstrated previously. Here, it was shown that TNF as an endogenous maturation stimulus and pathogenic Trypanosoma brucei variant-specific surface glycoproteins (VSG) induced highly similar DC gene expression signatures which instructed default effector Th2 responses. Repetitive administration of the differentially conditioned semi-mature DC effectively skewed T cell immunity to IL-10+ Th2 cells, mediating immune deviation and suppression. Collectively, the data presented in this work provide novel insights how immature and partially mature DC phenotypes generate T cell tolerance mechanisms in vitro, which has important implications for the design of effective DC-targeted vaccines. Unravelling the DC maturation signatures is central to the long-standing quest to break tolerance mimicked by malignant tumours or re-establish immune homeostasis in allergic or autoimmune disorders.
Alveolar echinococcosis (AE) is a severe and life-threatening disease caused by the metacestode larva of the fox-tapeworm Echinococcus multilocularis. Parasite entry into the host evokes an early and potentially parasiticidal Th1 immune response that is gradually replaced by a permissive Th2 response. An immunoregulatory environment has also been reported in the host as the disease progresses. As a result of immunomodulation, E. multilocularis larvae persist in the host for decades without being expelled, and thus almost act like a perfect transplant. Very little is currently known on the molecular basis of the host immunomodulation by E. multilocularis. In this work, in vitro cultivation systems were used to assess the influence of metabolites released by the parasite larvae (E/S products) on host immune effector cells. E/S products of cultivated larvae that respresent the early (primary cells) and chronic (metacestode vesicles) phase of AE induced apoptosis and tolerogenic properties (poor responsiveness to LPS stimulation) in host dendritic cells (DC) whereas those of control larvae (protoscoleces) failed to do so. These findings show that the early infective stage of E. multilocularis induces tolerogenicity in host DC, which is most probably important for generating an immunosuppressive environment at an infection phase in which the parasite is highly vulnerable to host attacks. Interestingly, metacestode E/S products promoted the conversion of naïve CD4+ T-cells into Foxp3+ regulatory T-cells in vitro, whereas primary cell and protoscolex E/S products failed to do it. Since Foxp3+ regulatory T-cells are generally known to mediate immunosuppression, the present finding indicates that Foxp3+ regulatory T-cells, expanded by E/S products of the metacestode larva, could play a role in the parasite-driven immunomodulation of the host observed during AE. Furthermore, a substantial increase in number and frequency of suppressive Foxp3+ regulatory T-cells could be observed within peritoneal exudates of mice following intraperitoneal injection of E. multilocularis metacestodes, indicating that Foxp3+ regulatory T-cells could also play an important role in E. multilocularis-driven immunomodulation in vivo. Interestingly, a parasite activin ortholog, EmACT, secreted by metacestodes, was shown to expand host regulatory T-cells in a TGF-β-dependent manner, similarly to mammalian activin A. This observation indicated that E. multilocularis utilizes evolutionarily conserved TGF-β superfamily ligands, like EmACT, to expand host regulatory T-cells. Taken together, the present findings suggest EmACT, a parasite activin secreted by the metacestode and capable of expanding host regulatory T-cells, as an important player in the host immunomodulation by E. multilocularis larvae. Another parasite factor EmTIP, homologous to mammalian T-cell immunomodulatory protein (TIP) was characterized in this work. EmTIP could be detected in the secretions of the parasite primary cells and localized to the intercellular space within the parasite larvae. EmTIP blockade inhibited the proliferation of E. multilocularis primary cells and the formation of metacestode vesicles indicating a major role for parasite development. Furthermore, EmTIP evoked a strong release of IFN-γ by CD4+ T-cells hence suggesting that the secretion of this factor as a result of its role in parasite development could “secondarily” induce a potentially protective Th1 response. In conclusion, this work identified two molecules, EmACT and EmTIP, with high immunomodulatory potential that are released by E. multilocularis larvae. The data presented do provide insights into the mechanisms of parasite-driven host immunomodulation during AE that are highly relevant for the development of anti-parasitic immune therapies.
Kinasen der SRC-Familie (SFKs) sind sowohl in Wachstum und Metastasierung von Tumor- und Leukämiezellen als auch an prominenter Stelle in vielgestaltige Signalwege aller Immunzellen involviert. Eine Hemmung von SFKs ist damit ein vielversprechendes Mittel zur Therapie maligner Erkrankungen, kann aber darüber hinaus auch sehr effektiv zur Immunmodulation genutzt werden. Für den zur Therapie von CML und AML zugelassenen Tyrosinkinaseinhibitor (TKI) Dasatinib (Handelsname Sprycel®), für den unter anderem SFKs die Hauptziele darstellen, wurden, neben der antitumoralen Wirkung, sowohl immunsuppressive als auch immunstimulierende Effekte beschrieben. Aus diesem Grund könnte Dasatinib ein für die Modulation von Immunantworten sehr interessantes Hilfsmittel darstellen. In der vorliegenden Arbeit werden die hemmenden und fördernden Einflüsse von Dasatinib auf zwei Typen von Immunzellen genauer untersucht, um so die Auswirkungen einer Dasatinib-Behandlung auf Zellen des Immunsystems besser zu verstehen und sich das immunmodulatorische Potenzial von Dasatinib besser nutzbar machen zu können.
Der erste Teil der Arbeit beschäftigt sich mit der Untersuchung möglicher kombinatorischer Effekte zwischen Dasatinib und dem Glucocorticoid Dexamethason auf verschiedene Subsets von T-Zellen vor dem Hintergrund eines potentiellen Einsatzes der Kombination bei der allogenen Hämatopoetischen Stammzelltransplantation (HSCT) zur Separation von Graft-versus-Leukemia (GvL)-Effekten und der Graft-versus-host Disease (GvHD). Während keine kombinatorischen Effekte bei der Aktivierung von T-Zellen auftraten, ergaben sich bei der Untersuchung des Einflusses auf die Proliferation besonders in CD8+ T-Zellen additive Effekte durch die Kombination. Die Proliferation naiver T-Zell-Subsets wurde bereits durch die beiden Einzelsubstanzen alleine stark gehemmt. Dagegen waren Memory T-Zell-Subsets deutlich unempfindlicher, allerdings konnte durch eine Kombination von Dexamethason und Dasatinib auch die Proliferation dieser Memory Subsets effektiv gehemmt werden. Hierbei zeigten sich bei CD8+ Memory Subsets die deutlichsten synergistischen Effekte. Da eine Kombination in stärkerem Maße auch CD8+ gegenüber CD4+ Memory Subsets hemmt und diese Subsets unterschiedliche Rollen in der Induktion von GvL-Effekten und der Auslösung einer GvHD zu spielen scheinen, ist eine Steigerung der GvL-Effektivität durch die Medikamenten-Kombination bei gleichzeitiger Minimierung eines GvHD-Risikos in Zusammenhang mit anderen publizierten Ergebnissen durchaus denkbar. Weil eine starke Hemmung von virus-spezifischen T-Zellen nur bei sehr hohen Konzentrationen auftrat, ist zudem das Risiko einer Virus-Reaktivierung, die ein großes Problem bei einer HSCT darstellt, eher als gering einzuschätzen.
Der zweite Teil der Arbeit befasst sich mit dem Einfluss von Dasatinib auf aus Monozyten generierte Dendritische Zellen (moDCs) mit einem Fokus auf der Beeinflussung ihrer Migration. Während eine Behandlung mit Dasatinib nur sehr geringe Auswirkungen auf die Ausreifung der moDCs und die Expression von kostimulatorischen Molekülen hatte, führte eine Dasatinib-Behandlung zu einer Zeit- und Dosis-abhängigen Verringerung der Zytokinsekretion (IL-10 und IL-12). Im Gegensatz dazu hatte Dasatinib keinen Einfluss auf die phagozytotische Aktivität der moDCs und auf ihre Fähigkeit, Virus-spezifische T-Zell-Antworten auszulösen. Dasatinib zeigte dagegen einen deutlich steigernden Einfluss auf die Migration von moDCs gegen einen CCL19-Gradienten im Transwell-Assay, ohne die Expression des CCL19-Rezeptors CCR7 zu beeinflussen. Da ähnliche Migrations-steigernde Effekte auch bei einer Behandlung mit dem spezifischen SFK-Inhibitor SKI-1 auftraten, eine Behandlung mit Nilotinib, einem TKI der nicht auf SFKs wirkt, im Gegensatz dazu aber zu einer Hemmung der Migration führte, liegt es nahe dass die Migrations-steigernde Wirkung von Dasatinib über SFKs vermittelt wird. Dasatinib führte zu einer deutlichen Inhibierung der Phosphorylierung der inhibitorischen Immunrezeptoren Siglec-9 und Siglec-3 (CD33) ohne ihre Expressionslevel zu beeinflussen. Eine mit spezifischen Antikörpern durchgeführte Blockierung dieser Immunrezeptoren, deren ITIM-Domänen mutmaßlich von SFKs phosphoryliert werden, hatte eine deutliche Steigerung der Migration und eine verringerte Phosphorylierung von Siglec-9, Siglec-3 und SHP-2 zur Folge. Letztere ist eine Phosphatase, die nach Bindung an phosphorylierte ITIM-Domänen von Rezeptoren wie den Siglecs verschiedene Zielmoleküle dephosphoryliert. Die Ergebnisse dieser Arbeit legen nahe, dass die Migrations-steigernde Wirkung von Dasatinib über eine Hemmung von SFKs und daraus resultierend auf dem Wegfall eines inhibitorischen Signalwegs erfolgt. Diese Steigerung der Migration könnte in der Tumor-Therapie von großem Nutzen sein, da bei einer Vakzinierung mit autologen DCs, die mit Tumor-assoziierten Antigenen stimuliert wurden, die schlechte Einwanderung in die Lymphknoten eines der Hauptprobleme darstellt. Zur Überwindung dieses Problems könnte Dasatinib ein sehr effektives Hilfsmittel darstellen und die Therapie-Effizienz deutlich verbessern. Da Dasatinib aber auch eine ganze Reihe weiterer, sehr vielfältiger Einflüsse auf alle Arten von Immunzellen ausübt, scheint eine Verwendung spezifischer blockierender α-Siglec-Antikörper auf Grund geringerer Nebenwirkungen im Vergleich zu Dasatinib möglicherweise sogar noch deutlich besser geeignet zu sein, das Migrationsverhaltens Dendritischer Zellen positiv zu beeinflussen. Die Verwendung gegen Siglec-Rezeptoren gerichteter Antikörper als Adjuvantien könnte somit zu einem erfolgreicheren Einsatz der Vakzination mit Dendritischen Zellen in der Tumor-Therapie führen.
Dendritische Zellen (DC) spielen eine Schlüsselrolle im Immunsystem. Sie dienen als professionelle antigenpräsentierende Zellen und können eine antigenspezifische Immunantwort initiieren, indem sie naive T-Zellen primen.
DC können auch verwendet werden, um T-Zellen im Kontext der onkologischen Immuntherapie zu stimulieren. In vitro können sie leicht aus Monozyten differenziert werden. Die daraus resultierenden unreifen DC können bereits Antigene phagozytieren und präsentieren, sie aktivieren jedoch noch keine Immunantwort solange keines der aufgenommenen Antigene als pathogen erkannt wird. Die Ausreifung einer unreifen, tolerogenen DC zu einer immunogenen reifen DC kann, neben anderen Methoden, durch einen Cocktail aus TLR-Liganden oder Zytokinen erreicht werden. Die Auswahl der Substanzen in diesem Cocktail bestimmt den Phänotyp und die funktionellen Eigenschaften der resultierenden reifen DC. Einige der benötigten Fähigkeiten der DC in der Tumorimmuntherapie, wo sie aus Patientenmonozyten generiert, mit Tumorantigen beladen und dem Patienten wieder zugeführt werden sollen, umfassen die Migration zu den T-Zell-Zonen der Lymphknoten, Antigenpräsentation auf sowohl MHC-I- als auch MHC-II-Molekülen, Zytokinproduktion für die Direktion der T-Zell-Antwort wie IL-12p70, und die Expression von Oberflächenmarkern wie der kostimulatorischen Moleküle CD80 und CD86.
In der Vergangenheit wurde gezeigt, dass durch Zugabe von Prostaglandin E2 (PGE2) zu einem Cocktail mit dem synthetischen TLR3-Liganden poly-I:C und dem TLR7/8-Liganden R848 (Resiquimod) sowohl eine gute migratorische Fähigkeit als auch eine erhöhte IL-12p70-Produktion erreicht werden kann, während etwa die Fähigkeit zur Antigen-Kreuzpräsentation reduziert erschien. Anhand von Monozyten anonymer gesunder Spender beleuchtet diese Arbeit daher den Effekt von PGE2 auf monozytenderivierte DC näher, indem seine konzentrationsabhängige Wirkung auf deren Phänotyp untersucht wird. In den durchgeführten Versuchen wurde dabei die Expressionsdichte der Oberflächenmarker CD83, CD80 und CD86, HLA-DR und CCR7 sowie der monozytäre Marker CD14 durchflusszytometrisch analysiert. Die Ergebnisse zeigen bei Exposition mit PGE2 dosisabhängig eine Heraufregulation von CD80, CD83, CD86 und CCR7 in der Population reifer DC, deren Maximum in unteren mikromolaren Konzentrationen erreicht wird. Gleichzeitig induzierte PGE2 dosisabhängig auch die Entstehung einer zweiten Zellpopulation mit anderen Eigenschaften, die stattdessen den monozytären Marker CD14 re-exprimierte. Dies ist für künftige Studien eine interessante Beobachtung, da sie eine differenzierte Betrachtung beider resultierender Subpopulationen anregt.
Characterization of tolerogenic rat bone marrow-derived dendritic cells and regulatory T cells
(2010)
Tolerogenic dendritic cells (DC) and regulatory T (Treg) cells are able to prevent destructive immune responses. There is reason to hope that it may soon be possible to use DC and Treg cells to suppress immune responses antigen-specific, not only after transplantation, but also in the case of autoimmunity and allergy. At the moment, the generation of such cell types is very time-consuming and not suitable for clinical routine. In addition, it is not yet fully understood how these cells elicit a desired protective immune response in vivo and how the risks of an excessive immune suppression can be managed. The rat is one of the most important animal models in biomedical research. It is therefore surprising that tolerogenic DC and Treg cells in particular have not been more thoroughly investigated in this model. Thus, the aim of the present study was to systematically characterize these immune cells and investigate their impact on the immune system. Tolerogenic DC were generated from bone marrow precursors cultured with GM-CSF and IL-4 (= IL-4 DC). The proportion of naturally occurring Treg cells with a CD4posCD25posFoxp3pos phenotype comprises approximately 5-8% of the peripheral CD4pos T cells. The characterization of IL-4 DC revealed an up to 26-fold reduced expression of surface molecules such as MHC class II molecules, CD80, CD86, ICAM-1 and CD25 in comparison to mature splenic DC (S-DC). This low expression did not change when the cells where stimulated with different maturation-inducing signals such as replating, LPS, TNF- α and CD40L. Thus, these cells possess a robust phenotype resistant to maturation-inducing stimuli. IL-4 DC take up antigen via endocytosis and are not able to activate naïve T cells or to restimulate antigen-specific T cells. Furthermore, they are able to inhibit and prolongate mature S-DC induced T cell proliferation as well as mature S-DC induced restimulation of antigen-specific T cells, respectively. Thereby, the T cell proliferation was reduced up to 95%. This strong inhibitory effect was mediated within 24 hours in association with a reduced cytokine production (IL-2 about 49% and IFN-γ about 92%). The inhibitory properties of IL-4 DC don´t seem to be caused exclusively by the reduced expression of co-stimulatory molecules. In this study, the detection of the inhibitory molecules PD-L1 and PD-L2 on IL-4 DC suggests they have an impact on mediating inhibitory signals to the T cells. In addition, a suppressive effect of soluble factors was shown. The supernatant of one million IL-4 DC, collected after a 24 hour culture, suppressed mature S-DC induced proliferation of naïve T cells by about 90%. TGF-β, which was detected in the supernatant (up to 300 pg/ml), appears to be the causing soluble factor for this immune inhibition. By contrast, the supernatants of mature S-DC, which did not inhibit the activation of T cells, showed a TGF-β concentration of only about 100 pg/ml. The cytotoxic nitric oxide does not contribute to the IL-4 DC-mediated inhibition of T cell proliferation. The NO synthase inhibitor NMMA reduced the amount of NO by about 50%, but the decreased NO levels did not influence T cell proliferation. Indeed, IL-4 DC are not able to induce T cell proliferation, but this doesn´t mean that there is no change on the molecular level. For instance, T cells co-cultured with IL-4 DC during a first culture are not able to proliferate in the presence of mature S-DC during a second culture. This anergic-like state, however, could be abolished by adding exogenous IL-2. In addition, T cells co-cultured with IL-4 DC are able to inhibit the activation of naïve T cells. Naïve and activated T cells were not able to inhibit the mature S-DC induced T cell proliferation. This observation suggests the induction of Treg cells and was investigated in more detail. Indeed, flow cytometric analysis showed a 1.6-fold expansion of CD4posCD25posFoxp3pos T cells from naturally occurring Treg cells in the presence of IL-4 DC. Thereby, the expansion of CD4posCD25posFoxp3pos T cells occurs independently of the maturation state of DC. Both immature IL-4 DC as well as mature S-DC were able to expand the percentage of naturally occurring Treg cells. However, Treg cells pre-incubated with mature S-DC demonstrated a diminished inhibitory effect compared to Treg cells pre-incubated with IL-4 DC. Treg cells pre-incubated with IL-4 DC were able to inhibit the activation of naïve T cells. In this study it was shown that the regulatory potential of DC cannot be deduced solely by their phenotype or maturation state. Other factors, such as functional properties, need to taken into consideration, too. The induction of Treg cells with suppressive properties induced by in vitro generated tolerogenic IL-4 DC might provide an important mechanism for the maintenance of peripheral tolerance. However, for clinical application further investigation is necessary, not only to understand the interactions between tolerogenic DC and Treg cells, but also to investigate the impact of the transfer of a larger quantity of regulatory cells on the immune system of the recipient.
Cutaneous leishmaniasis is endemic in tropical and subtropical regions of the world. Effective vaccination strategies are urgently needed because of the emergence of drug-resistant parasites and severe side effects of chemotherapy. The research group of Heidrun Moll previously established a DC-based vaccination strategy to induce complete and long-lasting immunity to experimental leishmaniasis using LmAg-loaded and CpG ODN-activated DC as a vaccine carrier. Prevention of tissue damages at the site of L. major inoculation can be achieved if the BALB/c mice were systemically given LmAg-loaded BMDC that had been exposed to CpG ODN. The interest in further exploring the role of IL-4 aroused as previous studies allowed establishing that IL-4 was involved in the redirection of the immune response towards a type 1 profile. Thus, wt BALB/c mice or DC-specific CD11ccreIL-4Rα-/lox BALB/c mice were given either wt or IL-4Rα-deficient LmAg-loaded BMDC exposed or not to CpG ODN prior to inoculation of 2 x 105 stationary phase L. major promastigotes into the BALB/c footpad. The results provide evidence that IL4/IL-4Rα-mediated signaling in the vaccinating DC is required to prevent tissue damages at the site of L. major inoculation, as properly conditioned wt DC but not IL-4Rα-deficient DC were able to confer resistance. Furthermore, uncontrolled L. major population size expansion was observed in the footpad and the footpad draining LN in CD11ccreIL-4Rα-/lox mice immunized with CpG ODN-exposed LmAg-loaded IL-4Rα-deficient DC, indicating the influence of IL-4R-mediated signaling in host DC to control parasite replication. In addition, no footpad damage was observed in BALB/c mice that were systemically immunized with LmAg-loaded wt DC doubly exposed to CpG ODN and recombinant IL-4. Discussing these findings allow the assumption that triggering the IL4/IL4Rα signaling pathway could be a precondition when designing vaccines aimed to prevent damaging processes in tissues hosting intracellular microorganisms.